Skip Navigation

Who we are

We come from all around the world, bringing literally thousands of years of combined knowledge and expertise to our mission. We are specialists in biosimilar medicines creation, all along the value chain from cell line development to commercial manufacturing.

What we do

Our biosimilar assets include several biosimilar monoclonal antibodies and fusion proteins that are developed in our research & development centers located across Europe and are manufactured in our state-of-the-art facility in Reykjavik, Iceland.

We develop, produce and release our biosimilars in-house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products to our partners worldwide.


Alvotech is a global leader in biosimilar medicines, developing the highest quality biosimilars and making them accessible to patients around the world for enhanced quality of life. The company’s state-of-the-art facility in Reykjavík is designed to meet highest FDA and EMA GMP requirements globally.

Our operations are fully integrated, with drug substance, drug products and quality control testing and release within the same location, to support a lean and efficient flow. We are using single use technology to minimize cleaning validation and product changes over time.

Robust manufacturing

Thanks to our robust manufacturing processes, we have reduced the need to clean and sterilize equipment and allowed for flexible and multiproduct manufacturing.

Alvotech has cutting-edge in-house R&D capabilities – from cell line development, process development and upscaling, completed by a fully integrated clinical and regulatory department allowing for a smooth transition from development through global launch and commercial manufacturing

The company has over 400 employees across four locations in three countries, Iceland, Germany and Switzerland. The headquarters and manufacturing facility are in Reykjavik, Iceland.

Our vision

Our vision is to set a new standard for the future of biopharmaceuticals by bringing high quality biosimilars to market for life-threatening diseases for patients around the world.